Key considerations for transitioning patients receiving bispecific therapy between care settings are highlighted.
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
Haumschild asks Cain about obstacles to optimal transitions of care between academic and community settings when utilizing bispecific antibodies. Cain identifies time constraints as a key barrier, highlighting the importance of timely consultation and communication around patient urgency when transferring to an academic center. He also notes geographic and financial barriers like long travel distances and limited resources to cover transportation, housing, and other expenses related to seeking care at distant specialized centers. Rural and economically disadvantaged patients may be especially impacted. Cain explains how his group has worked to increase community access to mitigate some of these barriers. He contrasts the robust infrastructure needed to facilitate academic referrals with the streamlined processes enabled by administering bispecific therapies locally. The discussion centers on overcoming obstacles through coordination across care settings to ensure optimal patient transitions.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More